Review of how tumor-associated neutrophils shape the lung adenocarcinoma microenvironment and potential neutrophil-targeted therapies.
Key Takeaways
- Despite the advances in immune checkpoint inhibitors (ICIs), primary and acquired resistance remain major obstacles
- Major challenges, including off-target toxicity, infection risk, and the lack of predictive biomarkers, are discussed
- Under chronic stimulation within the TME, neutrophils can be skewed towards a pro-tumorigenic “N2-like” phenotype